| Keywords: |
cancer survival; gene mutation; cancer recurrence; cancer combination chemotherapy; cancer radiotherapy; temozolomide; positron emission tomography; follow up; progression free survival; enzyme inhibition; protein targeting; genetic variability; editorial; antineoplastic activity; phosphatidylinositol 3 kinase; cancer resistance; glioblastoma; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; brain biopsy; 3' fluorothymidine f 18; drug tumor level; everolimus; rapamycin; pik3ca gene; pten gene; phase 2 clinical trial (topic); mammalian target of rapamycin complex 1; mammalian target of rapamycin complex 2; pik3r1 gene; human; sonolisib
|
